Boost for mRNA as Moderna to acquire OriCiro for $85 million
pharmaphorum
JANUARY 5, 2023
However, its messenger RNA (mRNA) platform – building on continuous advances in basic and applied mRNA science – permits the development of therapeutics and vaccines for other infectious diseases, immune-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases as well.
Let's personalize your content